| 3/3/2023 | BKCVDDEMHY | Prospect News reports no new defaults for Feb. 23-March 1
|
| 2/24/2023 | DD | Akorn Holding files Chapter 7 bankruptcy case in Delaware court
|
| 10/1/2020 | DD | Akorn exits Chapter 11 protection, completes sale to lenders
|
| 9/30/2020 | DD | Akorn reports $2.59 million operating loss for August period
|
| 9/8/2020 | DD | Akorn modified plan of reorganization confirmed by bankruptcy court
|
| 9/2/2020 | DD | Akorn gets bankruptcy court approval to sell assets via credit bid
|
| 8/31/2020 | DD | Akorn sees Chapter 11 plan rejected by three of four voting classes
|
| 8/28/2020 | DD | Akorn operating loss narrows to $7.54 million in July; revenue down
|
| 8/12/2020 | DD | Akorn plan confirmation and asset sale hearings adjourned to Sept. 1
|
| 8/7/2020 | DD | Akorn says Aug. 10 auction canceled; sale hearing set for Aug. 20
|
| 7/31/2020 | DD | Akorn records $9.21 million operating loss for month ended June 30
|
| 7/2/2020 | DD | Akorn disclosure statement OK’d; plan confirmation hearing Aug. 20
|
| 7/1/2020 | DD | Akorn seeks approval of $10 million sale of interests in non-debtor
|
| 6/15/2020 | DD | Akorn receives final court approval to access $30 million DIP loan
|
| 6/15/2020 | DD | Akorn asset sale procedures approved; auction scheduled for Aug. 10
|
| 6/3/2020 | DD | Akorn five-member official committee of unsecured creditors appointed
|
| 5/28/2020 | DD | Akorn files Chapter 11 plan in parallel with lender lead bid motion
|
| 5/26/2020 | DD | Moody’s downgrades Akorn
|
| 5/26/2020 | DD | Akorn first-day motions OK’d; Nasdaq expected to delist common stock
|
| 5/26/2020 | BKDD | Moody’s downgrades Akorn
|
| 5/22/2020 | BKCVDDEMHY | Prospect News reports eight new defaults for week of May 14-May 20
|
| 5/22/2020 | DD | Akorn interim DIP financing approved; final hearing set for June 15
|
| 5/21/2020 | BKDD | S&P drops Akorn to D
|
| 5/21/2020 | BKDD | Akorn files Chapter 11 bankruptcy, reaches bid agreement with lenders
|
| 4/3/2020 | BKDD | S&P drops Akorn to CC
|
| 2/20/2020 | BK | Moody's cuts Auris Luxembourg II
|
| 2/20/2020 | BKDD | Moody's downgrades Akorn
|
| 2/14/2020 | BKDD | S&P lowers Akorn
|
| 2/12/2020 | BKDD | Akorn enters standstill agreement with lenders, eyes sale of business
|
| 6/7/2019 | BKBWCVHY | Akorn battles high leverage, will address debt in Q3; ABL on horizon
|
| 4/17/2019 | BK | Akorn amends ABL revolver, extends by 90 days, lowers undrawn fee
|
| 1/16/2019 | BK | S&P downgrades Akorn
|
| 12/14/2018 | BKDD | Moody’s downgrades Akorn
|
| 11/14/2018 | BK | S&P changes Akorn view to negative
|
| 10/17/2018 | BK | Moody's downgrades Akorn
|
| 10/3/2018 | BK | S&P affirms Akorn
|
| 5/11/2018 | BK | S&P downgrades Akorn, debt
|
| 4/23/2018 | BKCV | Moody’s changes review on Akorn
|
| 3/6/2018 | BKCV | S&P changes Akorn to developing
|
| 4/26/2017 | BK | Moody’s could raise Akorn
|
| 4/11/2017 | BKCV | S&P: Akorn on positive watch
|
| 12/20/2016 | BKDDHY | S&P acts on U.S. pharmaceuticals
|
| 5/20/2016 | BKCV | S&P upgrades Akorn
|
| 5/11/2016 | BKCV | S&P changes Akorn watch to positive
|
| 2/29/2016 | BKCV | S&P keeps Akorn on developing watch
|
| 2/25/2016 | BK | Akorn makes voluntary $200 million prepayment on term loan facility
|
| 11/19/2015 | CL | Market Commentary: CLO gains from boosted pharma M&A may be curtailed amid drug pricing scrutiny; Valeant eyed
|
| 11/13/2015 | BK | Akorn lenders extend deadline for restated financials to August 2016
|
| 11/9/2015 | BKCV | S&P cuts Akorn ratings
|
| 9/25/2015 | PP | Market Commentary: Biotechnology names lower outright; AMAG Pharmaceuticals moves in line in active trade
|
| 9/25/2015 | CV | Market Commentary: Biotechnology names lower outright; AMAG Pharmaceuticals moves in line in active trade
|
| 7/7/2015 | SP | New Issue: Deutsche Bank prices $1.52 million phoenix autocallables tied to Akorn
|
| 7/1/2015 | SP | Deutsche Bank plans to price phoenix autocallables linked to Akorn
|
| 5/20/2015 | BK | Akorn gets waiver from lenders, additional flexibility to incur debt
|
| 3/10/2015 | PP | Market Commentary: Convertibles weaker as stocks sell off; BPZ Resources files bankruptcy; Akorn tumbles
|
| 3/10/2015 | CV | Market Commentary: Convertibles weaker as stocks sell off; BPZ Resources files bankruptcy; Akorn tumbles
|
| 8/15/2014 | BK | Akorn increases term loan financing with JPMorgan by $445 million
|
| 8/5/2014 | CV | Market Commentary: Convertibles weaker; Cobalt ‘comes in’ on hedge after earnings miss; Endeavour lower
|
| 8/5/2014 | CV | Market Commentary: Morning Commentary: Endeavour lower after earnings; GT Advanced Technologies, Akorn shares gain
|
| 7/7/2014 | CV | Market Commentary: Convertibles generally quiet; Macquarie Infrastructure on tap; Chinese internet paper eyed
|
| 6/24/2014 | BK | Market Commentary: TGI Fridays, LA Fitness, New Albertson’s, Bayonne Energy, Akorn, World Triathlon break
|
| 6/24/2014 | CLHY | Market Commentary: TGI Fridays, LA Fitness, New Albertson’s, Bayonne Energy, Akorn, World Triathlon break
|
| 6/19/2014 | BK | Market Commentary: DaVita, Wayne Fueling, Shearer’s Foods, Alstom second-lien, Equinox, Custom Sensors break
|
| 6/19/2014 | CLHY | Market Commentary: DaVita, Wayne Fueling, Shearer’s Foods, Alstom, Equinox, Custom Sensors break
|
| 6/19/2014 | BK | Akorn revises discount on $445 million incremental term loan to 99¾
|
| 6/10/2014 | BK | Market Commentary: Energy Future, Peak 10, Gray Television, Arizona Chem, Deltek break; Brickman moves deadline
|
| 6/10/2014 | CLHY | Market Commentary: Energy Future, Peak 10, Gray Television, Deltek break; Brickman moves deadline
|
| 6/10/2014 | BK | Akorn to launch $445 million incremental term loan on Thursday
|
| 6/3/2014 | BKCV | Moody's rates Akorn term loan add-on B1
|
| 5/14/2014 | BKCV | S&P: Akorn on watch
|
| 5/9/2014 | BK | Akorn plans $445 million term loan debt for VersaPharm purchase
|
| 5/9/2014 | BKCV | Moody's might cut Akorn
|
| 3/3/2014 | CV | Market Commentary: Tesla lags from issue; Yandex slumps on Russia-Ukraine conflict; Akorn down after earnings
|
| 3/3/2014 | CV | Market Commentary: Midday Commentary: New Teslas down again outright, on hedge; Akorn slips on hedge after guidance
|
| 11/13/2013 | BK | Market Commentary: RPI Finance, Akorn, Arby's, Husky break; Zayo dips with repricing; Filtration moves deadline
|
| 10/31/2013 | BK | Akorn firms $600 million term loan at Libor plus 350 bps, tightens OID
|
| 10/31/2013 | BK | Market Commentary: Bennu frees up; Microsemi, Akorn revised; BJ's, Crosby, RPI set talk; CSC discount emerges
|
| 10/16/2013 | BKCV | S&P rates Akorn loan B+
|
| 10/16/2013 | BKCV | Moody's gives Akorn CFR, loan B1
|
| 10/16/2013 | BK | Akorn launches $600 million term loan at Libor plus 350-375 bps
|
| 10/16/2013 | BK | Market Commentary: Gentiva Health, Renaissance Learning, Insight Global, Utility Services, Sinclair break
|
| 10/10/2013 | BK | Akorn readies Wednesday launch for $600 million term loan
|
| 10/10/2013 | BK | Market Commentary: Harvey Gulf breaks; Gentiva, Insight Global, Huntsman revise deals; Omnitracs discloses talk
|
| 9/13/2013 | CV | Market Commentary: ViroPharma jumps on takeout chatter; new Protalix moves up outright; GSV Capital gains
|
| 9/9/2013 | BK | Akorn outlines expected pricing on $675 million credit facility
|
| 8/28/2013 | BK | Akorn planned credit facility to include $75 million revolver
|
| 8/27/2013 | BK | Akorn plans $600 million of term loan borrowings for Hi-Tech purchase
|
| 5/17/2013 | CV | Market Commentary: Tesla pares gains in active debut; short-dated NetApp, Microsoft trade mixed; Akorn slips
|
| 8/27/2012 | CV | Market Commentary: Hertz trades up after deal to buy Dollar Thrifty; Akorn firms; Navistar gains as CEO retires
|
| 6/1/2011 | CV | Akorn greenshoe lifts 3.5% convertibles due 2016 to $120 million
|
| 5/31/2011 | CV | Citigroup top U.S. market convertibles underwriter for year to date
|
| 5/26/2011 | CV | New Issue: Akorn sells $100 million five-year convertibles to yield 3.5%, up 30%
|
| 5/26/2011 | CV | Market Commentary: Akorn trades up on debut; NetApp gains outright after raised guidance; Cubist in action
|
| 5/25/2011 | CV | Market Commentary: Horizon drops amid 'trading noise'; Medtronic mixed; Akorn's $100 million deal looks cheap
|
| 5/25/2011 | CV | Akorn to price $100 million five-year convertible notes to yield 3.5%-4%, up 25%-30%
|
| 3/16/2010 | PP | New Issue: Akorn sells $2.5 million of its common stock through private placement
|
| 1/9/2009 | SS | SAC Capital slashes stake to less than 1% in Akorn
|
| 11/20/2007 | PP | New Issue: Akorn to raise $7.01 million from private placement of stock
|
| 10/30/2006 | BT | Akorn quarterly sales up 32%, gross profit up 62%
|
| 9/18/2006 | BT | Akorn to ship $3.5 million order to U.S. government
|
| 9/11/2006 | PP | Market Commentary: Schuff raises $30 million from notes offering; Foothills pockets $22.5 million from PIPE
|
| 9/8/2006 | PP | Market Commentary: HyperSpace raises $4.55 million from convertibles; Akorn wraps $3.56 million stock sale
|
| 9/8/2006 | BTPP | New Issue: Akorn concludes $3.56 million private placement of stock
|
| 8/30/2006 | BT | Akorn completes early buyout of equipment lease
|
| 8/17/2006 | BT | Akorn, FDC seek approval for generic ophthalmic solution
|
| 8/10/2006 | BT | Akorn, Sofgen to develop, market anti-nausea drug
|
| 8/1/2006 | BT | Akorn to test AK-1015 in ocular anesthesia trial
|
| 7/28/2006 | BT | Akorn's diltiazem hydrochloride injection approved
|
| 7/24/2006 | BT | Akorn's ANDA for Diltiazem Hydrochloride Injection for high blood pressure, chest pain, approved
|
| 6/7/2006 | BT | Akorn gets approval for Sufenta injection
|
| 5/2/2006 | BT | Akorn, Fidia sign agreement to develop four drug products
|
| 4/24/2006 | BT | Akorn gets supplemental NDA approval for Inapsine nausea treatment
|
| 4/24/2006 | BT | Natco, Akorn form agreement for injectable drugs
|
| 3/28/2006 | BT | Akorn, Natco sign agreement to market anti-nausea drugs
|
| 3/20/2006 | BT | Akorn receives aNDA approval for ophthalmic solution
|
| 3/7/2006 | BT | Akorn, Cipla sign 10-year agreement for an oral anti-infective aNDA product
|
| 3/2/2006 | PP | Market Commentary: Novelos prepares to close $15.05 million stock deal; MediGene plans €15.63 million PIPE
|
| 3/1/2006 | BT | Market Commentary: Cepheid follow-on on deck; Akorn bags $19.4 million; Novavax results priced in; Exubera buoys Nektar
|
| 3/1/2006 | PP | Market Commentary: Akorn secures $19.4 million from private placement; Procera closes $6 million stock deal
|
| 3/1/2006 | BTPP | New Issue: Akorn to close $19.4 million private placement of stock
|
| 2/13/2006 | BT | Akorn gets $21.5 million funding approval for Calcium-DTPA, Zinc-DTPA
|
| 12/30/2005 | BT | U.S. government buys $21.5 million worth of Akorn's Ca-DTPA, Zn-DTPA for national stockpile
|
| 12/19/2005 | BT | Akorn, Natco sign deal to develop, supply two generic drugs with $800 million market
|
| 12/14/2005 | BT | Akorn to sign deal with Azad for development of three generic injectable drugs
|
| 11/8/2005 | BT | Akorn, Cipla strike deal to develop, manufacture anti-infective ANDA drug
|
| 8/18/2004 | CV | New Issue: Akorn sells $14.1 million 6% convertible preferreds in private placement
|
